Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVG-ASFV vaccine
- Development stage
- Preclinical
- Lead developer
- TVG
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular, Oronasal
01
Overview
TVG-ASFV is a veterinary viral-vector vaccine developed by The Vaccine Group (TVG) for the prevention of African swine fever (ASF) in pigs. The vaccine utilizes a proprietary herpesvirus-based viral vector platform to deliver and express specific African Swine Fever Virus (ASFV) antigens. This approach is designed to induce a robust immune response, including both humoral and cellular components, to protect swine against the highly contagious and lethal ASFV. Preclinical studies have demonstrated the vaccine's immunogenicity in pigs, showing its potential as a protective measure against the disease.
- Other names
- African swine fever vaccineASFV vaccine
02
Targets
ASFV (African swine fever virus)
Beyond the preview
Go deeper on TVG-ASFV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVG-ASFV vaccine.